FDA Requires New GLP-1 Drug Warnings About a Potential Risk of Rare but Permanent Vision Loss

semaglutide and even newer therapies like orforglipron.

Various medications and prescriptions displayed, highlighting eye health treatments.

The scope of products affected underscores how central GLP-1 RAs have become in modern care. According to the FDA communication, labeling changes will apply to exenatide, liraglutide, liraglutide plus insulin degludec, dulaglutide, lixisenatide plus insulin glargine, semaglutide in all its marketed forms, tirzepatide, and orforglipron. Although the original Byetta new drug application has been withdrawn, generic exenatide versions are still available and fall under the new warning. Reports of NAION have occurred with all currently marketed GLP-1 RA products, which is why the

Leave a Reply

Your email address will not be published. Required fields are marked *